170 related articles for article (PubMed ID: 413937)
21. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients.
Prout GR; Griffin PP; Nocks BN; DeFuria MD; Daly JJ
J Urol; 1982 Jun; 127(6):1096-8. PubMed ID: 6806488
[TBL] [Abstract][Full Text] [Related]
22. Unanticipated vesicoureteral reflux: a possible sequela of long-term thio-tepa instillations to the bladder.
Mukamel E; Glanz I; Nissenkorn I; Cytron S; Servadio C
J Urol; 1982 Feb; 127(2):245-6. PubMed ID: 6801270
[TBL] [Abstract][Full Text] [Related]
23. [Thio-tepa treatment for prevention of recurrence of surgically treated bladder tumors].
Neagoe M
Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir; 1980; 29(4):259-65. PubMed ID: 6457322
[TBL] [Abstract][Full Text] [Related]
24. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
25. [Verification of the effectiveness of Thio-Tepa on tumor tissue in local chemotherapy of bladder papillomatosis].
Lunglmayr G; Kellner G; Czech K
Urol Int; 1970; 25(5):493-501. PubMed ID: 5004171
[No Abstract] [Full Text] [Related]
26. [Cell kinetics of the bladder carcinoma. II. Effects of thio-TEPA on proliferative kinetics of the cultured human bladder carcinoma cells (author's transl)].
Kato T
Nihon Hinyokika Gakkai Zasshi; 1976 Jul; 67(7):497-501. PubMed ID: 823357
[No Abstract] [Full Text] [Related]
27. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study.
Heney NM; Koontz WW; Barton B; Soloway M; Trump DL; Hazra T; Weinstein RS
J Urol; 1988 Dec; 140(6):1390-3. PubMed ID: 3143016
[TBL] [Abstract][Full Text] [Related]
28. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.
Soloway MS; Jordan AM; Murphy WM
Prog Clin Biol Res; 1989; 310():215-36. PubMed ID: 2505268
[TBL] [Abstract][Full Text] [Related]
29. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
30. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
31. Severe pancytopenia associated with the use of intravesical thio-TEPA.
Watkins WE; Kozak JA; Flanagan MJ
J Urol; 1967 Oct; 98(4):470-1. PubMed ID: 4964489
[No Abstract] [Full Text] [Related]
32. [Intravesical application of thio-tepa for preventing postoperative recurrence of bladder carcinoma].
Zhang SX; Deng XZ; Tang XD
Zhonghua Wai Ke Za Zhi; 1986 Aug; 24(8):486-7, 510. PubMed ID: 3102180
[No Abstract] [Full Text] [Related]
33. [Dibunol and thio-TEPA treatment of bladder tumors].
Barsel' VA
Urol Nefrol (Mosk); 1978; (4):27-30. PubMed ID: 98889
[No Abstract] [Full Text] [Related]
34. A trial of prophylactic thiotepa or mitomycin C intravesical therapy in patients with recurrent or multiple superficial bladder cancers.
Flanigan RC; Ellison MF; Butler KM; Gomella LG; McRoberts JW
J Urol; 1986 Jul; 136(1):35-7. PubMed ID: 3086575
[TBL] [Abstract][Full Text] [Related]
35. Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa.
Wood DP; Streem SB; Levin HS
J Urol; 1988 Jan; 139(1):130-1. PubMed ID: 3121867
[TBL] [Abstract][Full Text] [Related]
36. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
37. Renal failure associated with the use of thio-tepa.
Schellhammer PF
J Urol; 1973 Nov; 110(5):498-501. PubMed ID: 4201562
[No Abstract] [Full Text] [Related]
38. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer.
Br J Urol; 1985 Dec; 57(6):680-5. PubMed ID: 2867800
[TBL] [Abstract][Full Text] [Related]
39. First-line chemotherapy of superficial bladder cancer: mitomycin vs thiotepa.
Heney NM
Urology; 1985 Oct; 26(4 Suppl):27-9. PubMed ID: 3931325
[TBL] [Abstract][Full Text] [Related]
40. Long-term intravesical thiotepa treatment in patients with superficial bladder tumors and vesicoureteral reflux.
Nissenkorn I; Servadio C; Vilikowski E; Glanz I
J Urol; 1985 Feb; 133(2):198-9. PubMed ID: 3918177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
